U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C50H68N14O10.C2H4O2
Molecular Weight 1085.2147
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BREMELANOTIDE ACETATE

SMILES

CC(O)=O.CCCC[C@H](NC(C)=O)C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC4=CC=CC=C4)NC(=O)[C@H](CC5=CN=CN5)NC1=O)C(O)=O

InChI

InChIKey=MAYUSRUHXFWITM-GBRHMYBBSA-N
InChI=1S/C50H68N14O10.C2H4O2/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32;1-2(3)4/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55);1H3,(H,3,4)/t35-,36-,37-,38+,39-,40-,41-;/m0./s1

HIDE SMILES / InChI
Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C50H68N14O10
Molecular Weight 1025.1627
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 1
Optical Activity UNSPECIFIED

Description

Bremelanotide (formerly PT-141) was developed for the treatment of female sexual dysfunction, hemorrhagic shock, and reperfusion injury. Bremelanotide, a synthetic peptide analog of α-melanocyte-stimulating hormone (α-MSH) is an agonist at melanocortin receptors including the MC3R and MC4R, which are expressed primarily in the central nervous system. Bremelanotide originally was tested for intranasal administration in treating female sexual dysfunction but this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. It appears that development for hemorrhagic shock and reperfusion injury has been discontinued. Palatin Technologies licensed North American development and commercialization rights of bremelanotide to Amag in January 2017. In June 2018, the US Food and Drug Administration (FDA) accepted AMAG Pharmaceuticals’ new drug application for bremelanotide for treatment of hypoactive sexual desire disorder in premenopausal women. If approved, bremelanotide will be available as a self-administered, disposable subcutaneous auto-injector used in anticipation of a sexual encounter.

Originator

Approval Year

2019
334
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
Agonist
2752
Agonist
2752
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
72.8 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
1.75 mg single, subcutaneous
dose: 1.75 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
BREMELANOTIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
276 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
1.75 mg single, subcutaneous
dose: 1.75 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
BREMELANOTIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.7 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
1.75 mg single, subcutaneous
dose: 1.75 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
BREMELANOTIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
79%
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
1.75 mg single, subcutaneous
dose: 1.75 mg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
BREMELANOTIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Disc. AE: Nausea, Headache...
Other AEs: Nausea, Flushing...
AEs leading to
discontinuation/dose reduction:
Nausea (8%)
Headache (2%)
Vomiting (1%)
Flushing (1%)
Injection site reactions (1%)
Flu-like symptoms (grade 1-2, <1%)
Increased blood pressure (grade 1-2, <1%)
Other AEs:
Nausea (grade 1-2, 40%)
Flushing (grade 1-2, 20.3%)
Injection site reactions (grade 1-2, 13.2%)
Headache (grade 1-2, 11.3%)
Vomiting (grade 1-2, 4.8%)
Cough (grade 1-2, 3.3%)
Fatigue (grade 1-2, 3.2%)
Hot flush (grade 1-2, 2.7%)
Paraesthesia (grade 1-2, 2.6%)
Dizziness (grade 1-2, 2.2%)
Nasal congestion (grade 1-2, 2.1%)
Upper abdominal pain (grade 1-2, <2%)
Diarrhea (grade 1-2, <2%)
Myalgia (grade 1-2, <2%)
Arthralgia (grade 1-2, <2%)
Pain (grade 1-2, <2%)
Restless leg syndrome (grade 1-2, <2%)
Rhinorrhea (grade 1-2, <2%)
Creatine phosphokinase increased (grade 1-2, <2%)
Blood pressure increased (grade 1-2, <2%)
Pain in extremity (grade 1-2, <2%)
Hyperpigmentation skin (grade 1-2, <2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
20 mg 1 times / day single, intranasal
Highest studied dose
Dose: 20 mg, 1 times / day
Route: intranasal
Route: single
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
healthy, mean age 32.7
Health Status: healthy
Age Group: mean age 32.7
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
Other AEs: Flushing...
Other AEs:
Flushing (mild, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
20 mg 1 times / day single, intranasal
Highest studied dose
Dose: 20 mg, 1 times / day
Route: intranasal
Route: single
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
healthy, mean age 32.7
Health Status: healthy
Age Group: mean age 32.7
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
Other AEs: Vomiting, Feeling hot...
Other AEs:
Vomiting (mild, 16.7%)
Feeling hot (mild, 33.3%)
Somnolence (mild, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
1.75 mg 3 times / week multiple, subcutaneous
Dose: 1.75 mg, 3 times / week
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
unhealthy, mean age 38.5
Health Status: unhealthy
Age Group: mean age 38.5
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
Other AEs: Paresthesia, Injection site erythema...
Other AEs:
Paresthesia (grade 1-2, 2.6%)
Injection site erythema (grade 1-2, 2.9%)
Injection site pruritus (grade 1-2, 2.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
10 mg 1 times / day single, subcutaneous
MTD
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: single
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
healthy
Health Status: healthy
Sex: M
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
Other AEs: Vomiting...
Other AEs:
Vomiting (grade 1-2, 50%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
AEs

AEs

AESignificanceDosePopulation
Flushing 1%
Disc. AE
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Injection site reactions 1%
Disc. AE
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Vomiting 1%
Disc. AE
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Headache 2%
Disc. AE
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Nausea 8%
Disc. AE
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Headache grade 1-2, 11.3%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Injection site reactions grade 1-2, 13.2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Nasal congestion grade 1-2, 2.1%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Dizziness grade 1-2, 2.2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Paraesthesia grade 1-2, 2.6%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Hot flush grade 1-2, 2.7%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Flushing grade 1-2, 20.3%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Fatigue grade 1-2, 3.2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Cough grade 1-2, 3.3%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Vomiting grade 1-2, 4.8%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Nausea grade 1-2, 40%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Flu-like symptoms grade 1-2, <1%
Disc. AE
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Increased blood pressure grade 1-2, <1%
Disc. AE
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Arthralgia grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Blood pressure increased grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Creatine phosphokinase increased grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Diarrhea grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Hyperpigmentation skin grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Myalgia grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Pain in extremity grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Pain grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Restless leg syndrome grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Rhinorrhea grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Upper abdominal pain grade 1-2, <2%
1.75 mg 10 times / 24 weeks multiple, subcutaneous
Recommended
Dose: 1.75 mg, 10 times / 24 weeks
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 10 times / 24 weeks
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
unhealthy, 19-56 years old
Health Status: unhealthy
Age Group: 19-56 years old
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
Flushing mild, 16.7%
20 mg 1 times / day single, intranasal
Highest studied dose
Dose: 20 mg, 1 times / day
Route: intranasal
Route: single
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
healthy, mean age 32.7
Health Status: healthy
Age Group: mean age 32.7
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
Somnolence mild, 16.7%
20 mg 1 times / day single, intranasal
Highest studied dose
Dose: 20 mg, 1 times / day
Route: intranasal
Route: single
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
healthy, mean age 32.7
Health Status: healthy
Age Group: mean age 32.7
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
Vomiting mild, 16.7%
20 mg 1 times / day single, intranasal
Highest studied dose
Dose: 20 mg, 1 times / day
Route: intranasal
Route: single
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
healthy, mean age 32.7
Health Status: healthy
Age Group: mean age 32.7
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
Feeling hot mild, 33.3%
20 mg 1 times / day single, intranasal
Highest studied dose
Dose: 20 mg, 1 times / day
Route: intranasal
Route: single
Dose: 20 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
healthy, mean age 32.7
Health Status: healthy
Age Group: mean age 32.7
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/14963471/
Injection site pruritus grade 1-2, 2.1%
1.75 mg 3 times / week multiple, subcutaneous
Dose: 1.75 mg, 3 times / week
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
unhealthy, mean age 38.5
Health Status: unhealthy
Age Group: mean age 38.5
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
Paresthesia grade 1-2, 2.6%
1.75 mg 3 times / week multiple, subcutaneous
Dose: 1.75 mg, 3 times / week
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
unhealthy, mean age 38.5
Health Status: unhealthy
Age Group: mean age 38.5
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
Injection site erythema grade 1-2, 2.9%
1.75 mg 3 times / week multiple, subcutaneous
Dose: 1.75 mg, 3 times / week
Route: subcutaneous
Route: multiple
Dose: 1.75 mg, 3 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
unhealthy, mean age 38.5
Health Status: unhealthy
Age Group: mean age 38.5
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/31599840/
Vomiting grade 1-2, 50%
10 mg 1 times / day single, subcutaneous
MTD
Dose: 10 mg, 1 times / day
Route: subcutaneous
Route: single
Dose: 10 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
healthy
Health Status: healthy
Sex: M
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252

inducer
1087
inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2A6
879

CYP2C19
2057

CYP2E1
1060

CYP2B6
926

CYP2C8
1057

OATP1B3
961

P-gp
1741

OAT3
747

BCRP
910

OAT1
725

OATP1B1
1079

OCT2
779
CYP1A2
832

CYP2B6
669

CYP2C19
329
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
OAT3
749
 low [Inhibition 1 uM]
OATP1B3
970
 low [Inhibition 1 uM]
P-gp
1932
 low [Inhibition 1 uM]
BCRP
985
 low
OAT1
730
 low
OATP1B1
1095
 low
OCT2
782
 low
CYP2A6
911
 no [Inhibition 200 uM]
CYP3A4
2633
 no [Ki 16 uM]
CYP2C19
2141
 no [Ki 35 uM]
CYP1A2
2333
 no
CYP1A2
2333
 no
CYP2B6
1160
 no
CYP2B6
1160
 no
CYP2C19
2141
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP2D6
2546
 no
CYP2E1
1146
 no
CYP3A4
2633
 no
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
Acorn PharmaTech
ACN-057294
http://www.acornpharmatech.com/
BioSynth
Q-200747
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/Q-200747.html
BOC Sciences
189691-06-3
https://www.bocsci.com/bremelanotide-cas-189691-06-3-item-61871.html
Chemenu
CM101686
http://www.chemenu.com/products/CM101686
Chemspace
CSSB02125551071
https://chem-space.com/CSSB02125551071
eNovation Chemicals
D679352
https://www.enovationchem.com/ProductDetails.asp?ProductID=D679352
Hairui
BRCQ032
http://www.hairuichem.com/en/product/189691-06-3.html
iChemical
EBD19124
http://www.ichemical.com/products/189691-06-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
MolPort
MolPort-009-194-183
https://www.molport.com/shop/molecule-link/MolPort-009-194-183
MuseChem
M043676
https://www.musechem.com/product/M043676.html
Smolecule
S522013
http://www.smolecule.com/products/s522013
THE BioTek
bt-242583
https://www.thebiotek.com/product/peptides/bt-242583
THE BioTek
bt-261470
https://www.thebiotek.com/product/inhibitors/bt-261470
PubMed

PubMed

TitleDatePubMed
Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.
2017-03
Re: Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial.
2016-11
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.
2016-06
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.
2003-06

Sample Use Guides

In Vivo Use Guide
Subjects will self-administer a fixed dose of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours.
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Wed Apr 02 05:06:29 GMT 2025
Edited
by admin
on Wed Apr 02 05:06:29 GMT 2025
Record UNII
PV2WI7495P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
L-LYSINE, N-ACETYL-L-NORLEUCYL-L-.ALPHA.-ASPARTYL-L-HISTIDYL-D-PHENYLALANYL-L-ARGINYL-L-TRYPTOPHYL-, (2->7)-LACTAM, ACETIC ACID (1:1)
Preferred Name English
BREMELANOTIDE ACETATE
USAN  
Official Name English
PT-141
Code English
BREMELANOTIDE ACETATE [USAN]
Common Name English
VYLEESI
Brand Name English
BREMELANOTIDE ACETATE [MI]
Common Name English
BREMELANOTIDE ACETATE [ORANGE BOOK]
Common Name English
N-ACETYL-L-2-AMINOHEXANOYL-L-.ALPHA.-ASPARTYL-L-HISTIDYL-D-PHENYLALANYL-L-ARGINYL-L-TRYPTOPHYL-L-LYSINE-(2->7)-LACTAM MONOACETATE (SALT)
Systematic Name English
Bremelanotide acetate [WHO-DD]
Common Name English
Code System Code Type Description
NCI_THESAURUS
C171917
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
SMS_ID
300000011161
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
DAILYMED
PV2WI7495P
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
EPA CompTox
DTXSID801027730
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
CAS
1607799-13-2
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
FDA UNII
PV2WI7495P
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
PUBCHEM
91971505
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
USAN
GH-124
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
RXCUI
2176311
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
DRUG BANK
DBSALT002878
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
MERCK INDEX
m12151
Created by admin on Wed Apr 02 05:06:29 GMT 2025 , Edited by admin on Wed Apr 02 05:06:29 GMT 2025
PRIMARY
Related Record Type Details
Structure of BREMELANOTIDE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BREMELANOTIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966